A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...
Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, ...
Some foods have beneficial properties, whereas others can cause harm, especially where geographic atrophy (GA) is concerned. The dietary choices you make can accelerate the progression of this ...
Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures BRISBANE, Calif., ...
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...
Please provide your email address to receive an email when new articles are posted on . The first disease-modifying therapies have transformed the management of geographic atrophy. Patient selection ...
Age is a major risk factor for geographic atrophy (GA). As the eyes age, natural defenses weaken, blood flow may decline, and waste removal may slow, allowing deposits called drusen to build up.
Learning to adapt to life with geographic atrophy (GA), one woman finds new ways to stay true to her adventurous spirit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results